SCI Pharmtech Inc is a Taiwan-based company mainly engaged in the research, development, manufacturing, and sales of active pharmaceutical ingredients (APIs), API intermediates, and specialty and precision chemicals. The Company's main product categories are APIs, API intermediates, and specialty chemicals. The Company primarily sells its products in Europe, Asia, the Americas, and other domestic and international markets.

Employees

239

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-21	NT$53.40	+1.14%	67,350
26-10-20	NT$52.80	+0.76%	107,817
26-10-19	NT$52.40	-2.06%	233,913
26-10-16	NT$53.50	+0.19%	42,792
26-10-15	NT$53.40	-2.91%	123,784

End-of-day quote Taiwan S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - SCI Pharmtech, Inc.

Company calendar

End-of-day quote Taiwan S.E. 2026-10-21			5-day change	1st Jan Change
53.40 ^TWD	+1.14%		-2.91%	+9.65%

08-06	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	6.32B 195M 174M 161M 145M 274M 18.39B 277M 1.93B 756M 9.67B 731M 716M 30.8B	P/E 2024	20.3x	P/E 2025	54.2x
Enterprise Value	7.23B 223M 199M 184M 166M 314M 21.04B 317M 2.21B 866M 11.06B 837M 819M 35.25B	EV / Sales 2024	7.3x	EV / Sales 2025	5.01x
Free-Float	54.76%	Yield 2024	1.66%	Yield 2025	1.54%

08-06	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-07	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-05	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-05	SCI Pharmtech, Inc. Proposes Dividend Distribution for the Period from January 1, 2025 to December 31, 2025	CI
11-07	SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-06	SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-05	SCI Pharmtech, Inc. Announces Cash Dividend, Payable on August 5, 2025	CI
25-05-26	SCI Pharmtech, Inc. Announces Changes to its Board, Effective May 26, 2025	CI
25-05-08	SCI Pharmtech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-10	Sci Pharmtech, Inc. Declares Dividend for Period from January 01, 2024 to December 31, 2024	CI
25-03-09	SCI Pharmtech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-01-09	Sci Pharmtech, Inc. Announces Cash Dividend Payment	CI
24-12-20	Sci Pharmtech, Inc. Announces Appointment of Members of the Sustainable Development Committee	CI

22-06-29	SCI Pharmtech : Notice of appointment of general manager of the Board of Directors.	PU
22-06-29	SCI Pharmtech : Notice of the re-election of chairman of the Board of Directors.	PU
22-06-21	SCI Pharmtech : List of the Company's elected directors.	PU
22-06-21	SCI Pharmtech : Notice of the resolutions of 2022 general shareholders' meeting.	PU
22-06-21	SCI Pharmtech : Notice of re-election of functional committees' members	PU

SCI Pharmtech, Inc. Stock

Stocks

4119

TW0004119003

Pharmaceuticals

Valuation: SCI Pharmtech, Inc.

Chart: SCI Pharmtech, Inc.

Latest news: SCI Pharmtech, Inc.

Press Releases: SCI Pharmtech, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: SCI Pharmtech, Inc.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 day	+1.14%
1 week	-2.91%
Current month	-3.78%
1 month	-6.81%
3 months	+10.33%
6 months	+11.13%
Current year	+9.65%

1 week	51.7	54
1 month	51.7	58.3
Current year	39.6	60.7
1 year	39.6	60.7
3 years	39.6	100.5
5 years	39.6	119.56
10 years	39.6	119.56

Manager	Title	Age	Since
Wei Chun Weng CEO	Chief Executive Officer	64	-
Wen Chen Yang DFI	Director of Finance/CFO	-	2002-12-31
Wen Chih Chou PRN	Corporate Officer/Principal	-	2010-08-31

Director	Title	Age	Since
Wei Chun Weng CHM	Chairman	64	2001-12-16
Hsiang Li Chen BRD	Director/Board Member	61	2001-12-16
Wen Chih Chou BRD	Director/Board Member	-	2010-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCI PHARMTECH, INC.	+1.14%	-2.91%	-8.40%	-40.00%	197M
ELI LILLY AND COMPANY	+1.70%	+5.13%	+58.93%	+117.36%	1,133B
JOHNSON & JOHNSON	+1.35%	+1.52%	+34.34%	+68.48%	621B
ABBVIE INC.	-0.46%	+0.47%	+23.08%	+94.76%	503B
ROCHE HOLDING AG	-0.96%	+2.34%	+38.54%	+63.59%	379B
MERCK & CO., INC.	+1.12%	+1.70%	+71.06%	+45.98%	370B
NOVARTIS AG	+0.77%	+1.45%	+21.80%	+51.15%	292B
ASTRAZENECA PLC	+1.11%	-0.03%	+1.23%	+25.68%	262B
AMGEN INC.	+0.77%	+2.87%	+45.56%	+57.22%	237B
GILEAD SCIENCES, INC.	+0.95%	+0.02%	+23.77%	+97.39%	190B
Average	+0.71%	+2.89%	+30.99%	+58.16%	398.82B
Weighted average by Cap.	+0.84%	+3.73%	+40.77%	+79.75%

	2024	2025
Net sales	1.52B 46.97M 41.85M 38.75M 35.07M 66.07M 4.43B 66.85M 465M 182M 2.33B 176M 173M 7.42B	1.34B 41.42M 36.91M 34.17M 30.92M 58.26M 3.91B 58.95M 410M 161M 2.05B 155M 152M 6.55B
Net income	535M 16.48M 14.69M 13.6M 12.3M 23.18M 1.56B 23.46M 163M 63.97M 817M 61.83M 60.54M 2.61B	107M 3.31M 2.95M 2.73M 2.47M 4.66M 312M 4.71M 32.74M 12.85M 164M 12.42M 12.16M 523M
Net Debt	298M 9.17M 8.18M 7.57M 6.85M 12.9M 866M 13.06M 90.75M 35.61M 455M 34.42M 33.7M 1.45B	912M 28.12M 25.06M 23.2M 21M 39.56M 2.65B 40.03M 278M 109M 1.39B 106M 103M 4.45B